Complement inhibitory proteins expression in placentas of thrombophilic women Complement inhibitory proteins expression in placentas of thrombophilic women
oleh: Przemysław Krzysztof Wirstlein, Piotr Jasiński, Marcin Rajewski, Tomasz Goździewicz, Jana Skrzypczak
| Format: | Article |
|---|---|
| Diterbitkan: | Via Medica 2012-10-01 |
Deskripsi
Factors controlling complement activation appear to exert a protective effect on pregnancy. This is<br />particularly important in women with thrombophilia. The aim of this study was to determine the transcript and<br />protein levels of complement decay-accelerating factor (DAF) and membrane cofactor protein (MCP) in the<br />placentas of women with acquired and inherited thrombophilia. Also, we assessed immunohistochemistry staining<br />of inhibitors of the complement cascade, DAF and MCP proteins, in the placentas of thrombophilic women.<br />Placentas were collected from eight women with inherited thrombophilia and ten with acquired thrombophilia.<br />The levels of DAF and MCP transcripts were evaluated by qPCR, the protein level was evaluated by Western<br />blot. We observed a higher transcript (p &lt; 0.05) and protein (p &lt; 0.001) levels of DAF and MCP in the placentas<br />of thrombophilic women than in the control group. DAF and MCP were localized on villous syncytiotrophoblast<br />membranes, but the assessment of staining in all groups did not differ. The observed higher expression level of<br />proteins that control activation of complement control proteins is only seemingly contradictory to the changes<br />observed for example in the antiphospholipid syndrome. However, given the hitherto known biochemical changes<br />associated with thrombophilia, a mechanism in which increased expression of DAF and MCP in the placentas is<br />an effect of proinflammatory cytokines, which accompanies thrombophilia, is probable.<br>Factors controlling complement activation appear to exert a protective effect on pregnancy. This is<br />particularly important in women with thrombophilia. The aim of this study was to determine the transcript and<br />protein levels of complement decay-accelerating factor (DAF) and membrane cofactor protein (MCP) in the<br />placentas of women with acquired and inherited thrombophilia. Also, we assessed immunohistochemistry staining<br />of inhibitors of the complement cascade, DAF and MCP proteins, in the placentas of thrombophilic women.<br />Placentas were collected from eight women with inherited thrombophilia and ten with acquired thrombophilia.<br />The levels of DAF and MCP transcripts were evaluated by qPCR, the protein level was evaluated by Western<br />blot. We observed a higher transcript (p &lt; 0.05) and protein (p &lt; 0.001) levels of DAF and MCP in the placentas<br />of thrombophilic women than in the control group. DAF and MCP were localized on villous syncytiotrophoblast<br />membranes, but the assessment of staining in all groups did not differ. The observed higher expression level of<br />proteins that control activation of complement control proteins is only seemingly contradictory to the changes<br />observed for example in the antiphospholipid syndrome. However, given the hitherto known biochemical changes<br />associated with thrombophilia, a mechanism in which increased expression of DAF and MCP in the placentas is<br />an effect of proinflammatory cytokines, which accompanies thrombophilia, is probable.